Beyond Air XAIR Stock
Beyond Air Price Chart
Beyond Air XAIR Financial and Trading Overview
| Beyond Air stock price | 5.61 USD |
| Previous Close | 7.49 USD |
| Open | 7.21 USD |
| Bid | 3.89 USD x 200 |
| Ask | 6.92 USD x 200 |
| Day's Range | 5.3 - 7.28 USD |
| 52 Week Range | 5.3 - 95.6 USD |
| Volume | 83.1K USD |
| Avg. Volume | 16.75K USD |
| Market Cap | 3.93M USD |
| Beta (5Y Monthly) | 0.224 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -80.2 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 160 USD |
XAIR Valuation Measures
| Enterprise Value | 17.22M USD |
| Trailing P/E | N/A |
| Forward P/E | -3.2831326 |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | 0.5113808 |
| Price/Book (mrq) | 5.6476684 |
| Enterprise Value/Revenue | 2.243 |
| Enterprise Value/EBITDA | -0.668 |
Trading Information
Beyond Air Stock Price History
| Beta (5Y Monthly) | 0.224 |
| 52-Week Change | -88.14% |
| S&P500 52-Week Change | 20.36% |
| 52 Week High | 95.6 USD |
| 52 Week Low | 5.3 USD |
| 50-Day Moving Average | 9.03 USD |
| 200-Day Moving Average | 21.56 USD |
XAIR Share Statistics
| Avg. Volume (3 month) | 16.75K USD |
| Avg. Daily Volume (10-Days) | 12.81K USD |
| Shares Outstanding | 720.53K |
| Float | 706.15K |
| Short Ratio | 1.1 |
| % Held by Insiders | 2.14% |
| % Held by Institutions | 9.66% |
| Shares Short | 16.59K |
| Short % of Float | 2.35% |
| Short % of Shares Outstanding | 2.29% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor | 1:20 |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | March 31, 2026 |
| Most Recent Quarter (mrq) | March 31, 2026 |
| Next Fiscal Year End | March 31, 2027 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | -375.98% |
| Gross Margin | 3.28% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -55.47% |
| Return on Equity (ttm) | -334.13% |
Income Statement
| Revenue (ttm) | 7.68M USD |
| Revenue Per Share (ttm) | 18.5 USD |
| Quarterly Revenue Growth (yoy) | 65.50% |
| Gross Profit (ttm) | 252K USD |
| EBITDA | -25793000 USD |
| Net Income Avi to Common (ttm) | -33249000 USD |
| Diluted EPS (ttm) | -80.2 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 11.64M USD |
| Total Cash Per Share (mrq) | 16.16 USD |
| Total Debt (mrq) | 23.38M USD |
| Total Debt/Equity (mrq) | 376.55 USD |
| Current Ratio (mrq) | 3.804 |
| Book Value Per Share (mrq) | 0.965 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -18144000 USD |
| Levered Free Cash Flow (ttm) | -14123375 USD |
Profile of Beyond Air
| Country | United States |
| State | NY |
| City | Garden City |
| Address | 900 Stewart Avenue |
| ZIP | 11530 |
| Phone | 516 665 8200 |
| Website | https://www.beyondair.net |
| Industry | Medical Devices |
| Sector(s) | Healthcare |
| Full Time Employees | 54 |
Beyond Air, Inc. operates as a commercial-stage medical device and biopharmaceutical company. It operates through Beyond Air, Beyond Cancer, and NeuroNos segments. The company offers Lungfit PH for the treatment of persistent pulmonary hypertension of the newborn. It is also developing LungFit PRO to treat viral lung infections, such as viral community-acquired pneumonia, including COVID-19 and bronchiolitis in hospitalized patients; and LungFit GO for the treatment of nontuberculous mycobacteria (NTM). In addition, the company develops ultra-high concentration NO (UNO) that is in Phase 1 clinical trial to treat solid tumors; and selective neuronal nitric oxide synthase (nNOS) inhibitor for the treatment of neurological conditions. It has a collaboration with the Yissum Research Development Company of the Hebrew University of Jerusalem, LTD to acquire the commercial rights for neuronal nitric oxide synthase inhibitors to treat autism spectrum disorder and other neurological conditions. The company was formerly known as AIT Therapeutics, Inc. and changed its name to Beyond Air, Inc. in June 2019. Beyond Air, Inc. was founded in 2011 and is headquartered in Garden City, New York.
Q&A For Beyond Air Stock
What is a current XAIR stock price?
Beyond Air XAIR stock price today per share is 5.61 USD.
How to purchase Beyond Air stock?
You can buy XAIR shares on the Tech Market Small exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Beyond Air?
The stock symbol or ticker of Beyond Air is XAIR.
Which industry does the Beyond Air company belong to?
The Beyond Air industry is Medical Devices.
How many shares does Beyond Air have in circulation?
The max supply of Beyond Air shares is 720.53K.
What is Beyond Air Price to Earnings Ratio (PE Ratio)?
Beyond Air PE Ratio is now.
What was Beyond Air earnings per share over the trailing 12 months (TTM)?
Beyond Air EPS is -80.2 USD over the trailing 12 months.
Which sector does the Beyond Air company belong to?
The Beyond Air sector is Healthcare.
Beyond Air XAIR included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
|
|
{{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
US Tech Composite
IXIC
US
|
26269.23 USD — |
+0.62
|
6.33B USD — | 26041.13 USD — | 26316.81 USD — | — - | 6.33B USD — |
|
US Tech Capital Market Composite
RCMP
US
|
140.4 USD — |
+0.07
|
— — | 138.5 USD — | 141.42 USD — | — - | — — |
|
US Tech Health Care
IXHC
US
|
1251.97 USD — |
+0.86
|
— — | 1233.72 USD — | 1252.49 USD — | — - | — — |
- {{ link.label }} {{link}}